TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12526238

Group type: EXPERIMENTAL
Intervention: Skin-to-skin holding for 2 hours for 2 consecutive days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Incubator care
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Skin-to-skin holding
Number of subjects: 14
Study: 10950445

Group type: EXPERIMENTAL
Intervention: Hiking poles (E)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No hiking poles (C)
Number of subjects: 20
Study: 9386146

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol (1 mg sublingual)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (sublingual)
Number of subjects: 16
Study: 7938102

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (P) treatment (group 1)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Early remission with P (group 2a)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Early remission without P (group 2b)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (group 3)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Groups 1 and 2
Number of subjects: 56
Study: 3162501

Group type: EXPERIMENTAL
Intervention: Rigid contact lenses
Number of subjects: 25

Group type: COMPARATOR
Intervention: Soft contact lenses
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Rigid contact lenses (recovery data)
Number of subjects: 25
Study: 29374988

Group type: EXPERIMENTAL
Intervention: Ankle block after tourniquet inflation with local incisional anesthetic at closure (Group C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ankle block after tourniquet inflation (Group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ankle block before tourniquet inflation (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Narcotic consumption
Number of subjects: 0
Study: 25153307

Group type: EXPERIMENTAL
Intervention: Black Currant Nectar (BCN)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 16
Study: 25637323

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg bid)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study: 24146219

Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin and intravenous rituximab (500 mg/m² twice/cycle) in CODOX-M/IVAC regimen
Number of subjects: 25
Study: 21210009

Group type: EXPERIMENTAL
Intervention: Feldspathic porcelain crowns (group 1)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Glass-infiltrated alumina all-ceramic crowns (group 2)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Both groups (group 1 and group 2)
Number of subjects: 33
Study: 17681303

Group type: EXPERIMENTAL
Intervention: Local injury to the endometrium
Number of subjects: 121

Group type: COMPARATOR
Intervention: Gene expression analysis
Number of subjects: 121
Study: 16256442

Group type: EXPERIMENTAL
Intervention: Peer advisor intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advanced practice nurse (APN) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 14617263

Group type: EXPERIMENTAL
Intervention: Oxygen administration
Number of subjects: 43

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 43
Study: 11037099

Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Decentring questions
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control questions
Number of subjects: 48
Study: 9113347

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) administration of melanotan-I at a dose of 0.16 mg/kg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) administration of melanotan-I at doses from 0.08 to 0.21 mg/kg
Number of subjects: 3

Group type: COMPARATOR
Intervention: Oral (PO) administration of melanotan-I at a dose of 0.16 mg/kg
Number of subjects: 3
Study: 8124289

Group type: EXPERIMENTAL
Intervention: White noise stimulus at 86 dB
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: White noise stimulus at 76 dB
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: White noise stimulus at 66 dB
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: White noise stimulus increased from 66 dB to 86 dB
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: White noise stimulus increased from 76 dB to 86 dB
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: White noise stimulus decreased from 86 dB
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Repeated auditory stimulation
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: White noise stimulus
Number of subjects: 89
Study: 3325593

Group type: EXPERIMENTAL
Intervention: 1% lignocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 0
Study: 29995186

Group type: EXPERIMENTAL
Intervention: Generic pegylated liposomal doxorubicin (SPIL DXR hydrochloride liposome injection)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Reference products (Caelyx or Doxil)
Number of subjects: 89
Study: 27350226

Group type: EXPERIMENTAL
Intervention: Carbetocin
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 263
Study: 25417402

Group type: EXPERIMENTAL
Intervention: Liandouqingmai recipe plus standard treatment for CHD
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard treatment only (Control)
Number of subjects: 101
Study: 22762964

Group type: EXPERIMENTAL
Intervention: Survey completion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Living with the patient
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Satisfaction with care and quality of dying
Number of subjects: 0
Study: 20391301

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 9
Study: 18831970

Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16896508

Group type: EXPERIMENTAL
Intervention: Pamidronate (30 mg daily for 3 days, total 90 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 32
Study: 14662571

Group type: EXPERIMENTAL
Intervention: 2-component acellular vaccine
Number of subjects: 667

Group type: COMPARATOR
Intervention: 5-component pertussis vaccine
Number of subjects: 667

Group type: COMPARATOR
Intervention: whole cell pertussis vaccine
Number of subjects: 667

Group type: COMPARATOR
Intervention: diphtheria and tetanus toxoids vaccine alone
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: 2-component pertussis vaccine with booster
Number of subjects: 667

Group type: COMPARATOR
Intervention: any of the vaccines
Number of subjects: 667
Study: 10992836

Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 32
Study: 8995031

Group type: EXPERIMENTAL
Intervention: rhGH 4 i.u./m2/day for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1603140

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg of calcium citrate malate per day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 70
Study: 3894128

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (pump treatment)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional insulin treatment
Number of subjects: 65
Study: 30289489

Group type: EXPERIMENTAL
Intervention: Negative age stereotypes priming
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Positive age stereotypes priming
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control condition (no priming)
Number of subjects: 114
Study: 29664000

Group type: EXPERIMENTAL
Intervention: BPLE‐CPR
Number of subjects: 279

Group type: COMPARATOR
Intervention: S‐CPR
Number of subjects: 279
Study: 26906164

Group type: EXPERIMENTAL
Intervention: Resistance exercise (six whole-body exercises, three sets, 8-10 repetitions, 70% 1RM)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (30min cycling, 60% VO2peak)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control condition (day prior to exercise)
Number of subjects: 14
Study: 24978856

Group type: EXPERIMENTAL
Intervention: HPV‐16/18 AS04‐adjuvanted vaccine
Number of subjects: 505
Study: 23707680

Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Perceived treatment allocation (active vs placebo)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Expected pain levels
Number of subjects: 101
Study: 20713756

Group type: EXPERIMENTAL
Intervention: Rupatadine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Levocetirizine
Number of subjects: 60
Study: 18787890

Group type: EXPERIMENTAL
Intervention: Active suction applied to the underwater seal drainage (group I)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Simple underwater seal drainage (group II)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 91
Study: 16438899

Group type: EXPERIMENTAL
Intervention: NPPV
Number of subjects: 342

Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 342
Study: 12885807

Group type: EXPERIMENTAL
Intervention: Semimonthly regimen of fluorouracil and leucovorin (LVFU2)
Number of subjects: 905

Group type: COMPARATOR
Intervention: Monthly regimen of fluorouracil and leucovorin (FULV)
Number of subjects: 905
Study: 11475269

Group type: EXPERIMENTAL
Intervention: Repaglinide 0.25 mg
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Repaglinide 0.5 mg
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Repaglinide 1 mg
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Repaglinide 2 mg
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Repaglinide 4 mg
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 8785252

Group type: EXPERIMENTAL
Intervention: Rifabutin
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1100
Study: 1877851

Group type: EXPERIMENTAL
Intervention: MaxEPA (eicosapentaenoic acid) 20 g daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Olive oil (placebo) 20 g daily
Number of subjects: 27
Study: 6781613

Group type: EXPERIMENTAL
Intervention: Oestradiol 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prostaglandin E2 (PGE2) 4 mg
Number of subjects: 0
Study: 30943184

Group type: COMPARATOR
Intervention: Best conventional scleral lenses
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Wavefront-guided (WFG) scleral lenses
Number of subjects: 10
Study: 28769121

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (60 min treadmill exercise at 59% peak oxygen uptake)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (resting throughout the trial)
Number of subjects: 47
Study: 26192383

Group type: EXPERIMENTAL
Intervention: Gain-framed message emphasizing benefits of avoiding IT
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Loss-framed message emphasizing risks of IT
Number of subjects: 475

Group type: COMPARATOR
Intervention: Self-affirmation manipulation
Number of subjects: 475

Group type: COMPARATOR
Intervention: Control condition (no self-affirmation)
Number of subjects: 475
Study: 24715380

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 912

Group type: COMPARATOR
Intervention: No endocrine treatment
Number of subjects: 912
Study: 22040311

Group type: EXPERIMENTAL
Intervention: 0.2% saline in 5% dextrose (hypotonic fluid group)
Number of subjects: 84

Group type: COMPARATOR
Intervention: 0.9% saline in 5% dextrose (isotonic fluid group)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study: 19630998

Group type: EXPERIMENTAL
Intervention: Suture closure of the pancreatic remnant
Number of subjects: 23
Study: 17582159

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 137

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone
Number of subjects: 137
Study: 16422961

Group type: EXPERIMENTAL
Intervention: Intracavernous injection of 1 mL bimix (30 mg papaverine + 1 mg phentolamine) followed by 1 mL mixture of papaverine and chlorpromazine (30 mg papaverine + 2.5 mg chlorpromazine)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intracavernous injection of 1 mL trimix (30 mg papaverine + 1 mg phentolamine + 10 microg PGE1) followed by 1 mL mixture of papaverine, PGE1, and chlorpromazine (30 mg papaverine + 2.5 mg chlorpromazine + 10 microg PGE1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Various intracavernous injections of chlorpromazine in doses 1 mg, 2 mg, 5 mg, and 10 mg
Number of subjects: 50
Study: 11883914

Group type: EXPERIMENTAL
Intervention: Chocolate condition (CC, N=13)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Bread and butter condition (BC, N=16)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Fixed chocolate condition (FS, N=20)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Variable chocolate condition (VS, N=18)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control condition (CS, N=15)
Number of subjects: 82
Study: 9652303

Group type: EXPERIMENTAL
Intervention: Allergen challenge in food-sensitized children
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo challenge in sensitized patients
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo challenge in non-sensitized group
Number of subjects: 26
Study: 8590553

Group type: EXPERIMENTAL
Intervention: Lactate infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic receptor blockade (propranolol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactate infusion with propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 0
Study: 2498781

Group type: EXPERIMENTAL
Intervention: Salbutamol 0.5 mg i.v. in 15 min (Group A)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Glucose 40 g i.v. plus 10 units insulin i.v. in 15 min (Group B)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Salbutamol 0.5 mg i.v., glucose 40 g i.v. and insulin 10 units i.v. over 15 min (Group C)
Number of subjects: 44
Study: 367714

Group type: COMPARATOR
Intervention: Levodopa alone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Levodopa and carbidopa (Sinemet)
Number of subjects: 21
Study: 31212041

Group type: EXPERIMENTAL
Intervention: Spaced instruction (four weekly sessions)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Massed instruction (two sequential days)
Number of subjects: 48
Study: 29165168

Group type: EXPERIMENTAL
Intervention: Winter sample (154 students)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Spring sample (147 students)
Number of subjects: 301
Study: 25384419

Group type: EXPERIMENTAL
Intervention: Self-management Acceptance and Commitment Therapy-based training intervention (ACTr)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Knowledge- and skills-based Dialectical Behaviour Training intervention (DBTr)
Number of subjects: 100
Study: 23511362

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 42
Study: 21804337

Group type: EXPERIMENTAL
Intervention: Laughter therapy (8 sessions, twice a week for 60 minutes each)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no laughter therapy)
Number of subjects: 37
Study: 18998161

Group type: EXPERIMENTAL
Intervention: Accuracy instructions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Implicit learning processes
Number of subjects: 0
Study: 18163861

Group type: EXPERIMENTAL
Intervention: Claims-based audit and feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Claims- and medical-record-based audit and feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Claims- and medical-record-based audit and feedback plus a practice-based diabetes resource nurse
Number of subjects: 0
Study: 14969665

Group type: EXPERIMENTAL
Intervention: Transdermal contraceptive system (Ortho Evra)
Number of subjects: 3319

Group type: COMPARATOR
Intervention: Oral contraceptive (OC)
Number of subjects: 3319

Group type: EXPERIMENTAL
Intervention: Transdermal contraceptive system (Ortho Evra) and Oral contraceptive (OC)
Number of subjects: 3319
Study: 12475842

Group type: EXPERIMENTAL
Intervention: INS316 (10 to 180 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 9649975

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Fluoxetine (in severe depression subsample)
Number of subjects: 44
Study: 8023691

Group type: EXPERIMENTAL
Intervention: Parental Bonding Instrument (PBI) assessment
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Parental Bonding Instrument (PBI) - affectionless control quadrant assignment
Number of subjects: 4
Study: 2589361

Group type: EXPERIMENTAL
Intervention: Intravenous/oral ciprofloxacin
Number of subjects: 71

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin
Number of subjects: 71
Study: 31902690

Group type: EXPERIMENTAL
Intervention: High Fidelity (HF) simulation model
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low Fidelity (LF) simulation model
Number of subjects: 36
Study: 29504059

Group type: EXPERIMENTAL
Intervention: Brisk walking program (3 sessions of 60 min per week for 6 months)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Brisk walking program
Number of subjects: 94
Study: 27281879

Group type: EXPERIMENTAL
Intervention: PHC Cage (polyaminoacid/nano-hydroxyapatite/calcium sulfate)
Number of subjects: 30

Group type: COMPARATOR
Intervention: PEEK Cage
Number of subjects: 30
Study: 25529410

Group type: EXPERIMENTAL
Intervention: Electrical Stimulation (ES) following Botulinum Toxin A (BoNT/A) injection
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (only daily stretch)
Number of subjects: 6
Study: 23249876

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 2633

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 2633
Study: 20516300

Group type: EXPERIMENTAL
Intervention: Round-ended bur
Number of subjects: 50

Group type: COMPARATOR
Intervention: Torpedo-shaped bur
Number of subjects: 50
Study: 19134273

Group type: EXPERIMENTAL
Intervention: Excel (bioabsorbable polymer sirolimus-eluting stent)
Number of subjects: 591

Group type: COMPARATOR
Intervention: Cypher (durable polymer sirolimus-eluting stent)
Number of subjects: 591
Study: 16155038

Group type: EXPERIMENTAL
Intervention: Oesophageal Doppler guided fluid management
Number of subjects: 128

Group type: COMPARATOR
Intervention: Central venous pressure (CVP)‐based fluid management
Number of subjects: 128
Study: 14768494

Group type: EXPERIMENTAL
Intervention: Selective beta-blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 10573659

Group type: COMPARATOR
Intervention: Creatine (Cr)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 16
Study: 10162149

Group type: EXPERIMENTAL
Intervention: VA hospital care
Number of subjects: 0

Group type: COMPARATOR
Intervention: County hospital care
Number of subjects: 0
Study: 1873013

Group type: EXPERIMENTAL
Intervention: Intravenous norepinephrine (NE) infusion
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Plasma NE levels
Number of subjects: 26
Study: 6329613

Group type: EXPERIMENTAL
Intervention: High-carbohydrate, high-fiber diet (HCF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 20
Study: 31169550

Group type: EXPERIMENTAL
Intervention: Neck-specific exercise (NSE)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Physical activity prescription
Number of subjects: 216
Study: 28620894

Group type: EXPERIMENTAL
Intervention: Three-trocar sleeve gastrectomy (experimental group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Five-trocar technique (control group)
Number of subjects: 90
Study: 28459237

Group type: EXPERIMENTAL
Intervention: Feiwei granules (FGs)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Jinshuibao capsules (JCs)
Number of subjects: 100
Study: 25106092

Group type: EXPERIMENTAL
Intervention: High molecular weight barley β‐glucan (3 g)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low molecular weight barley β‐glucan (3 g)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control soup with no β‐glucan
Number of subjects: 23
Study: 22071249

Group type: EXPERIMENTAL
Intervention: Standard-potency mOPV1
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Higher-potency mOPV1
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Intradermal IPV (GlaxoSmithKline)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Intramuscular IPV (GlaxoSmithKline)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Intramuscular IPV (Panacea)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Intradermal IPV
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Intramuscular IPV
Number of subjects: 1002
Study: 19671190

Group type: EXPERIMENTAL
Intervention: Artemisinin-naphthoquine combination (ANQ)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Chloroquine plus single dose sulphadoxine-pyrimethamine (CQ+SP)
Number of subjects: 100
Study: 17381474

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) and gonadotropin-releasing hormone agonist (GnRHa) treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: No intervention (untreated)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both treated and untreated groups
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GH/GnRHa treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both treated and untreated participants
Number of subjects: 30
Study: 15620935

Group type: EXPERIMENTAL
Intervention: Collagen-gentamicin (260 mg gentamicin) sponges applied within the sternotomy before wound closure
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Intravenous isoxazolyl-penicillin alone (control group)
Number of subjects: 2000
Study: 12048335

Group type: EXPERIMENTAL
Intervention: All-out start strategy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Even pacing strategy
Number of subjects: 8